The authors had previously demonstrated that PIK3CA mutations make CRC more dependent on glutamine and therefore the combination of a glutaminase inhibitor (CB-839) and 5-FU leads to notable regression of PIK3CA-mutant CRC in xenograft nude mouse models (5, 6). This evidence concerns the gene GLS and colorectal carcinoma.